CIBC Asset Management Inc reduced its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 16.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,814 shares of the medical instruments supplier’s stock after selling 2,251 shares during the quarter. CIBC Asset Management Inc’s holdings in West Pharmaceutical Services were worth $4,852,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of WST. Allworth Financial LP grew its position in shares of West Pharmaceutical Services by 140.0% during the 1st quarter. Allworth Financial LP now owns 72 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 42 shares in the last quarter. Addison Advisors LLC grew its position in shares of West Pharmaceutical Services by 221.7% during the 1st quarter. Addison Advisors LLC now owns 74 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 51 shares in the last quarter. Artemis Wealth Advisors LLC acquired a new position in shares of West Pharmaceutical Services during the 1st quarter worth approximately $35,000. American National Bank grew its position in shares of West Pharmaceutical Services by 55.6% during the 1st quarter. American National Bank now owns 98 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 35 shares in the last quarter. Finally, Dividend Assets Capital LLC acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth approximately $51,000. 93.25% of the stock is owned by institutional investors.
West Pharmaceutical Services Price Performance
WST stock opened at $341.70 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $275.89 and a 52-week high of $475.35. The company has a fifty day moving average price of $308.62 and a 200-day moving average price of $347.61. The company has a market capitalization of $25.30 billion, a P/E ratio of 37.92, a PEG ratio of 1.39 and a beta of 1.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.41 and a current ratio of 3.13.
Analyst Ratings Changes
Separately, StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, April 28th.
In related news, insider Silji Abraham sold 5,374 shares of the business’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the transaction, the insider now directly owns 3,201 shares in the company, valued at $1,100,919.93. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.